102
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database*

&
Pages 3009-3016 | Accepted 10 Oct 2007, Published online: 23 Oct 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Gregory Reardon, Sameer Kotak & Gail F Schwartz. (2011) Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Preference and Adherence 5, pages 441-463.
Read now
Miguel A Teus, Stefano Miglior, Guna Laganovska, Lāsma Volksone, Bozena Romanowska-Dixon, Roman Gos & Gábor Holló. (2009) Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology 3, pages 629-636.
Read now
Anders Bergström, Frédérique Maurel, Claude Le Pen, Emilie Lamure, Michael Kent, Isabelle Bardoulat & Gilles Berdeaux. (2009) Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden. Clinical Ophthalmology 3, pages 471-481.
Read now

Articles from other publishers (10)

Ngozika E. Ezinne, Chukwuebuka S. Ojukwu, Kingsley K. Ekemiri, Obinna F. Akano, Edgar Ekure & Uchechukwu Levi Osuagwu. (2021) Prevalence and clinical profile of glaucoma patients in rural Nigeria—A hospital based study. PLOS ONE 16:12, pages e0260965.
Crossref
Doreen Nelson-Ayifah & Khathutshelo P. Mashige. (2020) Demographic and clinical characteristics of patients with glaucoma in a tertiary eye facility in Ghana. African Vision and Eye Health 79:1.
Crossref
Daniel B. Horton, Harshvinder Bhullar, Lucy Carty, Francesca Cunningham, Alexis Ogdie, Janet Sultana & Gianluca Trifirò. 2019. Pharmacoepidemiology. Pharmacoepidemiology 241 289 .
Caroline Canavan, Joe West & Timothy Card. (2015) Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment. PharmacoEconomics 34:2, pages 181-194.
Crossref
Jennifer Burr & Luke Vale. 2015. Glaucoma. Glaucoma 509 513 .
Jens Olsen, Gilles Berdeaux & Jesper Skov. (2011) Glaucoma costs in Denmark in treatment naive patients. Acta Ophthalmologica 91:1, pages 25-31.
Crossref
Alexis Ogdie, Sinéad M. Langan, John Parkinson, Hassy Dattani, Karel Kostev & Joel M. Gelfand. 2012. Pharmacoepidemiology. Pharmacoepidemiology 224 243 .
Vicky H. Lu, Ivan Goldberg & Christine Y. Lu. (2010) Use of Glaucoma Medications: State of the Science and Directions for Observational Research. American Journal of Ophthalmology 150:4, pages 569-574.e9.
Crossref
Robert FaulknerNajam A. SharifSusan OrrKenneth SallHarvey DuBinerJess T. WhitsonMarlene MosterE. Randy CravenMichael CurtisCynthia PailliotetKimberly MartensDavid Dahlin. (2010) Aqueous Humor Concentrations of Bimatoprost Free Acid, Bimatoprost and Travoprost Free Acid in Cataract Surgical Patients Administered Multiple Topical Ocular Doses of LUMIGAN ® or TRAVATAN ® . Journal of Ocular Pharmacology and Therapeutics 26:2, pages 147-156.
Crossref
. (2009) Current World Literature. Current Opinion in Ophthalmology 20:2, pages 137-145.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.